Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. While popular drugs like Ozempic and Wegovy are ...

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Shares of Google parent Alphabet slump after quarterly revenue misses analysts’ expectations, AMD’s data-center revenue ...

Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.

Novo Nordisk shares rose Wednesday after fourth-quarter earnings ... People taking Wegovy start off on the lowest dose – or the starter dose – then work their way up to stronger formulations so their ...

The “magnificent seven” tech stocks have helped drive the U.S. stock market to record highs. Their soaring valuations imply ...

The Pseudobatch transformation is a method to easy analysis of measurement from a fed-batch fermentation process. After transformation, the data can be analysed as if it was obtained from a batch ...

Novo Nordisk hopes the new treatment can build on the success of its flagship obesity drug, Wegovy. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this ...

Novo Nordisk describes its latest work as "a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration." ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...